摘要 |
Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
|
申请人 |
GENENTECH, INC.;LOWE, DAVID;CUNNINGHAM, BRIAN, C.;OARE, DAVID;MCDOWELL, ROBERT, S.;BURNIER, JOHN |
发明人 |
LOWE, DAVID;CUNNINGHAM, BRIAN, C.;OARE, DAVID;MCDOWELL, ROBERT, S.;BURNIER, JOHN |